354 related articles for article (PubMed ID: 19553450)
1. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity.
Taylor TN; Caudle WM; Shepherd KR; Noorian A; Jackson CR; Iuvone PM; Weinshenker D; Greene JG; Miller GW
J Neurosci; 2009 Jun; 29(25):8103-13. PubMed ID: 19553450
[TBL] [Abstract][Full Text] [Related]
2. VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.
Taylor TN; Caudle WM; Miller GW
Parkinsons Dis; 2011 Feb; 2011():124165. PubMed ID: 21403896
[TBL] [Abstract][Full Text] [Related]
3. Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.
Taylor TN; Alter SP; Wang M; Goldstein DS; Miller GW
Neuropharmacology; 2014 Jan; 76 Pt A(0 0):97-105. PubMed ID: 24025942
[TBL] [Abstract][Full Text] [Related]
4. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease.
Colebrooke RE; Humby T; Lynch PJ; McGowan DP; Xia J; Emson PC
Eur J Neurosci; 2006 Nov; 24(9):2622-30. PubMed ID: 17100850
[TBL] [Abstract][Full Text] [Related]
5. A Pitx3-deficient developmental mouse model for fine motor, olfactory, and gastrointestinal symptoms of Parkinson's disease.
Song B; Feldmann JW; Cao S; Feitosa M; Kong Y; Kim W; Schweitzer A; Leblanc P; Schweitzer JS; Kim KS
Neurobiol Dis; 2022 Aug; 170():105777. PubMed ID: 35636646
[TBL] [Abstract][Full Text] [Related]
6. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration.
Caudle WM; Richardson JR; Wang MZ; Taylor TN; Guillot TS; McCormack AL; Colebrooke RE; Di Monte DA; Emson PC; Miller GW
J Neurosci; 2007 Jul; 27(30):8138-48. PubMed ID: 17652604
[TBL] [Abstract][Full Text] [Related]
7. Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice.
Kariya S; Takahashi N; Hirano M; Ueno S
J Mol Neurosci; 2005; 27(3):277-79. PubMed ID: 16280597
[TBL] [Abstract][Full Text] [Related]
8. VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.
Lohr KM; Miller GW
Expert Rev Neurother; 2014 Oct; 14(10):1115-7. PubMed ID: 25220836
[TBL] [Abstract][Full Text] [Related]
9. Improved functional and histochemical outcomes in l-DOPA plus tolcapone treated VMAT2-deficient mice.
Moreira CG; Morawska MM; Baumann A; Masneuf S; Linnebank M; Sommerauer M; Landolt HP; Noain D; Baumann CR
Neuropharmacology; 2020 Dec; 181():108353. PubMed ID: 33038358
[TBL] [Abstract][Full Text] [Related]
10. Mice with reduced vesicular monoamine storage content display nonmotor features of Parkinson's disease.
Vernon AC
J Neurosci; 2009 Oct; 29(41):12842-4. PubMed ID: 19828798
[No Abstract] [Full Text] [Related]
11. Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's disease.
Ma K; Han C; Zhang G; Guo X; Xia Y; Wan F; Yin S; Kou L; Liu L; Huang J; Xiong N; Wang T
Biochem Biophys Res Commun; 2019 May; 513(2):306-312. PubMed ID: 30954223
[TBL] [Abstract][Full Text] [Related]
12. The impact and management of nonmotor symptoms of Parkinson's disease.
Lyons KE; Pahwa R
Am J Manag Care; 2011 Oct; 17 Suppl 12():S308-14. PubMed ID: 22087551
[TBL] [Abstract][Full Text] [Related]
13. Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson's disease.
Langley MR; Ghaisas S; Palanisamy BN; Ay M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Exp Neurol; 2021 Jul; 341():113716. PubMed ID: 33839143
[TBL] [Abstract][Full Text] [Related]
14. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
[TBL] [Abstract][Full Text] [Related]
15. Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.
Alter SP; Stout KA; Lohr KM; Taylor TN; Shepherd KR; Wang M; Guillot TS; Miller GW
Exp Neurol; 2016 Jan; 275 Pt 1(Pt 1):17-24. PubMed ID: 26428905
[TBL] [Abstract][Full Text] [Related]
16. Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.
Hennis MR; Marvin MA; Taylor CM; Goldberg MS
Neurobiol Dis; 2014 Feb; 62():113-23. PubMed ID: 24075852
[TBL] [Abstract][Full Text] [Related]
17. Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice.
Isingrini E; Guinaudie C; C Perret L; Rainer Q; Moquin L; Gratton A; Giros B
Sci Rep; 2017 Sep; 7(1):12432. PubMed ID: 28963508
[TBL] [Abstract][Full Text] [Related]
18. Vesicular monoamine transporter 2 mediates fear behavior in mice.
Branco RC; Burkett JP; Black CA; Winokur E; Ellsworth W; Dhamsania RK; Lohr KM; Schroeder JP; Weinshenker D; Jovanovic T; Miller GW
Genes Brain Behav; 2020 Jun; 19(5):e12634. PubMed ID: 31898856
[TBL] [Abstract][Full Text] [Related]
19. Neuronal expression of familial Parkinson's disease A53T α-synuclein causes early motor impairment, reduced anxiety and potential sleep disturbances in mice.
Rothman SM; Griffioen KJ; Vranis N; Ladenheim B; Cong WN; Cadet JL; Haran J; Martin B; Mattson MP
J Parkinsons Dis; 2013; 3(2):215-29. PubMed ID: 23938351
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.
Branch SY; Chen C; Sharma R; Lechleiter JD; Li S; Beckstead MJ
J Neurosci; 2016 Apr; 36(14):4026-37. PubMed ID: 27053209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
